Wugen develops novel cellular therapies for human cancers. Wugen’s state-of-the-art gene editing technologies and cutting-edge cell therapy address key challenges that have limited the clinical use of cell therapies.

For more information, visit Wugen or follow their updates on:



  • $172m

Wugen Articles

Wugen and Balto Led Bumper Q3 of Venture Capital Funding in St. Louis

Adarza BioSystems Raises Another $25 Million to Launch Platform for Research and Drug Development

In 2019, BioGenerator Invested $3.2 Million in 16 Bioscience Companies in St. Louis